Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Recruiting now · Phase 2/Phase 3

Conditions studied: Potentially Resectable Hepatocellular Carcinoma

In brief

The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.

Key facts

Study ID

NCT06796803

Run by

Shanghai Zhongshan Hospital

People needed

398

Starts

2025-02-20

Expected to finish

2030-02-28

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed Informed Consent Form (ICF)
• Aged ≥18 years and ≤75 years at time of signing ICF
• Documented diagnosis of HCC confirmed by histology/cytology or clinically
• Patients with BCLC stage B (the sum of number of tumors and the maximum diameter of the largest tumor exceeding Up-to-7 criteria) and BCLC stage C without extrahepatic metastasis: ① tumors confined to one lobe (left, right, or middle lobe), or tumors in one lobe are present alongside a single tumor with diameter ≤5 cm or up to three tumors each with diameter ≤3 cm in the remaining lobes; ②No PVTT involving the contralateral liver lobe or reaching the superior mesenteric vein. And no tumor thrombus of the inferior vena cava reaching right atrium
• Patients with recurrence following prior radical surgical resection must have undergone the initial surgery at least 5 years prior to study entry
• At least one measurable lesion (per RECIST v1.1) untreated lesion
• ECOG performance status of 0 or 1
• Child-Pugh ≤7 score
• Life expectancy ≥12 weeks
• Adequate organ function
• No prior anti-tumor systemic therapies for HCC

You may not qualify if…

• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
• Other active malignant tumor except HCC within 5 years or simultaneously
• Prior locoregional therapy (such as TACE、TAE、HAIC、TARE)
• There is an absolute contraindication to HAIC
• History of hepatic encephalopathy
• Diffuse HCC, intrahepatic tumor burden > 50%
• PVTT reaching the superior mesenteric vein, and bilateral PVTT are present
• Clinically significant ascites
• Prior allogeneic stem cell or solid organ transplantation

Where it is running

• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China (enrolling)
• Zhongshan Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.